TearCare Procedure Proves Durable for Dry Eye Disease
TearCare Procedure Proves Durable for Dry Eye Disease 🕓 Estimated Reading Time: 5 minutes Overview Background & Context Implications & Analysis Reactions & Statements What Comes Next Conclusion Overview New clinical data has demonstrated that the TearCare System, an advanced treatment for Meibomian Gland Dysfunction (MGD), offers sustained benefits for patients suffering from Dry Eye Disease (DED) over a period of 24 months. The groundbreaking 24-month results of the SAHARA Randomized Controlled Trial (RCT), published in a peer-reviewed journal, indicate that a single TearCare procedure provides long-lasting relief from the chronic symptoms of dry eye. This significant finding underscores the potential of TearCare as a durable solution for millions worldwide grappling with this often debilitating ocular condition. The study’s long-term outcomes for TearCare dry eye patients signal a notable advancement in managing evaporative dry eye, which accounts for approximately 86% ...